Nautilus Launches Tau Early Access Program, Cuts Q1 Expenses 14%
Nautilus Biotechnology cut Q1 operating expenses by 14% to $16.1 million and narrowed its net loss to $14.7 million while holding $143.4 million in cash and investments as of March 31, 2026. The company launched its Tau proteoform Early Access Program and appointed Amber Faust as VP of Global Sales.
1. First Quarter Financial Results
Nautilus recorded operating expenses of $16.1 million in Q1 2026, a 14% decline from $18.8 million year-over-year. Net loss narrowed to $14.7 million from $16.6 million, and the company reported $143.4 million in cash and investments as of March 31, 2026.
2. Iterative Mapping Early Access Program
Nautilus initiated its Iterative Mapping Early Access Program, providing broader customer access to its Tau proteoform assay. Baylor College of Medicine became the first participant under an NIH-funded cancer study, supporting platform validation and future research publications.
3. Leadership Appointment and Commercialization Progress
Amber Faust joined as Vice President of Global Sales to spearhead customer expansion and drive adoption of the Voyager platform ahead of commercial launch. The company is also advancing a next-generation assay format to improve probe compatibility, performance and scalability.